Search clinical trials for: AK117 AK104

Total 185 results

Akeso

Not yet recruiting

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Resectable Non-small Cell Lung Cancer
Akeso
AD Pharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

Homozygous Familial Hypercholesterolemia

China
Gangnam Severance Hospital

Completed

Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients

Primary Open-angle Glaucoma
Akeso

Active, not recruiting

Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

SCLC, Extensive Stage

China
Janssen-Cilag, S.A.

Completed

PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder
Sun Yat-sen University

Recruiting

Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006) (EC-CRT-006)

Esophagus Cancer

China
Akeso

Recruiting

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

China
SamA Pharmaceutical Co., Ltd

Unknown

Safety, Pharmacokinetic Study of PRIC in Healthy Adult Subjects

Healthy

Korea, Republic of
Akeso
AD Pharmaceuticals Co., Ltd.

Completed

A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Heterozygous Familial Hypercholesterolemia

China
Summit Therapeutics
Akeso

Recruiting

Phase III Study of AK112 for NSCLC Patients

Non-Squamous Non-small Cell Lung Cancer

Canada, United States, Spain, Italy, France
Akeso
AD Pharmaceuticals Co., Ltd.

Completed

A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia

Hypercholesterolemia

China
Akeso
Peking University Cancer Hospital & Institute

Recruiting

A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Hodgkin Disease Lymphoma

China
Novartis Pharmaceuticals

Terminated

Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study (SWISSMASIA)

Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity

Switzerland
Lifefactors Zona Franca, SAS

Unknown

Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.

Coronavirus Disease 2019 (COVID-19)

Colombia
Akeso

Not yet recruiting

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

China
Summit Therapeutics
Akeso

Recruiting

Phase 3 Clinical Study of AK112 for NSCLC Patients

Non-Squamous Non-small Cell Lung Cancer

United States, Spain, China, France, Canada, Italy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC)

China
Akeso
Akeso Tiancheng, Inc

Completed

A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer

Squamous Cell Lung Cancer | Lung Cancer Non-small Cell Stage IV

China
RemeGen Co., Ltd.

Recruiting

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Akeso

Not yet recruiting

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
Liaoning Tumor Hospital & Institute
Huludao central hospital; Anshan Tumor Hospital; Chaoyang Central Hospital; Fukuang...

Not yet recruiting

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Breast Neoplasm Female
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
Sun Yat-sen University

Recruiting

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | Immune Checkpoint Inhibitor

China
Akeso

Completed

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer

China
Sun Yat-sen University

Recruiting

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Pleural Mesothelioma

China
Akeso

Recruiting

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer

China
Akeso
Akeso Tiancheng, Inc

Terminated

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

Lung Cancer Non-small Cell Stage IV

China
Akeso

Recruiting

A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

NSCLC

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Unresectable Metastatic Colorectal Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. (PAAG)

Pancreatic Neoplasms

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

China
RenJi Hospital
Shanghai Zhongshan Hospital; Ruijin Hospital

Recruiting

A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy

China
Sun Yat-sen University

Recruiting

Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer (OPTICAL-2)

Colorectal Cancer

China
Shanghai Chest Hospital
The Affiliated Hospital of Qingdao University; Zhejiang University; Anhui Provincial...

Recruiting

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) (AK104IIT018)

NSCLC Stage IV | NSCLC Stage IIIB | NSCLC Stage IIIC

China
Loyola University

Terminated

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis (CRO-OSTEO)

Osteomyelitis

United States

3

Subscribe